French Biotech that makes Drugs faster and cheaper IPO’s for €31M

14/07/2016 - 2 minutes

Pharnext has successfully completed its IPO on the Euronext Paris exchange, allowing it to move forward with Phase II and III trials for Neurological diseases that include Alzheimer’s.

pharnext_pxt3003_charcot_marie_tooth_cmt1aBased in Paris, Pharnext is developing new therapies for neurological conditions, including rare diseases such as Charcot-Marie-Tooth Disease.

New partners to join this biotech in the €31M IPO include Galapagos (the Belgian biotech working on Rheumatoid and cystic fibrosis) and the Institut Mérieux.

Pharnext uses network pharmacology to discover synergistic combinations of drugs (Pleodrugs) that can have a therapeutic effect in a given disease.

Pharnext’s most advanced pleodrug is PXT3003. It has already gone through Phase II trials, obtaining good results and working as a proof of concept for the pleotherapy platform.

PXT3003 targets Charcot-Marie-Tooth Disease Type 1A (CMT1A), a myelin-sheath degrading genetic disease which leads to progressive muscular atrophy (muscle wastage) leading to tremors and trouble using hands and feet.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member